Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 20 studies | 37% ± 17% | |
type I pneumocyte | 11 studies | 34% ± 10% | |
basal cell | 9 studies | 31% ± 7% | |
club cell | 8 studies | 34% ± 16% | |
endothelial cell | 5 studies | 19% ± 3% | |
adventitial cell | 5 studies | 30% ± 10% | |
adipocyte | 5 studies | 26% ± 7% | |
secretory cell | 4 studies | 26% ± 11% | |
myofibroblast cell | 4 studies | 31% ± 6% | |
smooth muscle cell | 3 studies | 28% ± 7% | |
epithelial cell | 3 studies | 19% ± 3% | |
respiratory goblet cell | 3 studies | 36% ± 12% |
Insufficient scRNA-seq data for expression of FMO2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 16311.35 | 575 / 578 | 86% | 14.41 | 996 / 1155 |
breast | 99% | 8379.19 | 454 / 459 | 72% | 10.53 | 808 / 1118 |
esophagus | 98% | 5291.56 | 1411 / 1445 | 60% | 14.40 | 109 / 183 |
thymus | 81% | 2098.67 | 530 / 653 | 25% | 1.06 | 152 / 605 |
kidney | 35% | 572.09 | 31 / 89 | 71% | 16.25 | 638 / 901 |
adrenal gland | 77% | 1955.65 | 199 / 258 | 25% | 1.53 | 57 / 230 |
adipose | 99% | 8087.77 | 1195 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 10078.09 | 1302 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 4637.37 | 823 / 861 | 0% | 0 | 0 / 0 |
prostate | 40% | 686.55 | 97 / 245 | 54% | 3.01 | 270 / 502 |
uterus | 61% | 1831.93 | 104 / 170 | 17% | 4.16 | 79 / 459 |
pancreas | 9% | 136.75 | 31 / 328 | 67% | 5.06 | 119 / 178 |
stomach | 33% | 779.99 | 118 / 359 | 36% | 2.87 | 102 / 286 |
muscle | 66% | 1128.73 | 531 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 62% | 25.86 | 28 / 45 |
skin | 28% | 619.11 | 499 / 1809 | 26% | 1.33 | 121 / 472 |
intestine | 35% | 683.05 | 335 / 966 | 17% | 2.30 | 91 / 527 |
ovary | 16% | 419.42 | 28 / 180 | 31% | 2.59 | 132 / 430 |
lymph node | 0% | 0 | 0 / 0 | 41% | 1.52 | 12 / 29 |
bladder | 24% | 349.48 | 5 / 21 | 15% | 1.85 | 75 / 504 |
brain | 1% | 14.98 | 29 / 2642 | 30% | 1.29 | 211 / 705 |
liver | 4% | 45.34 | 9 / 226 | 14% | 0.60 | 55 / 406 |
spleen | 2% | 30.29 | 5 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0097009 | Biological process | energy homeostasis |
GO_0070995 | Biological process | NADPH oxidation |
GO_0072592 | Biological process | oxygen metabolic process |
GO_0006739 | Biological process | NADP metabolic process |
GO_0009404 | Biological process | toxin metabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006082 | Biological process | organic acid metabolic process |
GO_0046322 | Biological process | negative regulation of fatty acid oxidation |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0047822 | Molecular function | hypotaurine dehydrogenase activity |
GO_0050661 | Molecular function | NADP binding |
GO_0004499 | Molecular function | N,N-dimethylaniline monooxygenase activity |
GO_0050660 | Molecular function | flavin adenine dinucleotide binding |
Gene name | FMO2 |
Protein name | Dimethylaniline oxidase 2 (FMO 1B1) (Pulmonary flavin-containing monooxygenase 2) Flavin-containing monooxygenase 2 (EC 1.14.13.-) (Dimethylaniline oxidase 2) (FMO 1B1) (Pulmonary flavin-containing monooxygenase 2) (FMO 2) |
Synonyms | |
Description | FUNCTION: Catalyzes the oxidative metabolism of numerous xenobiotics, including mainly therapeutic drugs and insecticides that contain a soft nucleophile, most commonly nitrogen and sulfur and participates to their bioactivation . Specifically catalyzes S-oxygenation of sulfur derived compounds such as thioureas-derived compounds, thioetherorganophosphates to their sulfenic acid . In vitro, catalyzes S-oxygenation of the second-line antitubercular drugs thiacetazone (TAZ) and ethionamide (ETA), forming a sulfinic acid and a carbodiimide via a postulated sulfenic acid intermediate . Also catalyzes S-oxygenation of the thioether-containing organophosphate insecticides, phorate and disulfoton . . |
Accessions | ENST00000529935.5 Q99518 ENST00000483192.2 A0A0D9SG76 A0A0D9SFZ0 ENST00000209929.10 |